^
    Back
    Association details:
    Biomarker:EGFR mutation
    Cancer:Non Small Cell Lung Cancer
    Drug Class:PD1 inhibitor +
    Angiogenesis inhibitor
    Direction:Resistant
    Evidence:
    Evidence Level:
    Resistant: C3 – Early Trials
    New
    Source:
    BMC Pulm Med
    Title:

    Efficacy and safety of combined immunotherapy and antiangiogenic therapy for advanced non-small cell lung cancer: a real-world observation study

    Published date:
    05/19/2023
    Excerpt:
    Patients with brain metastasis (p = 0.025), liver metastasis (p = 0.012), bone metastasis (p = 0.014) and EGFR mutations (p = 0.033) who received combination therapy with PD-1 inhibitors and antiangiogenic drugs had shorter OS…
    DOI:
    https://doi.org/10.1186/s12890-023-02470-z